NCT06527534View on ClinicalTrials.gov

Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

July 15, 2025

Study Completion Date

September 15, 2025

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Filgotinib

Patients will receive pills of Filgotinib 200 mg qd for 12 weeks

DRUG

Adalimumab

Patients will receive subcutaneous injections of Adalimumab 40 mg q2wk for 12 weeks

Trial Locations (1)

37100

RECRUITING

Rheumatology Section, University of Verona, Verona

All Listed Sponsors
lead

Universita di Verona

OTHER